The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Human antibody–Fc receptor interactions illuminated by crystal structures
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
RETH, M. (1989) · Nature · doi:10.1038/338383b0 · Cited by 1,438
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design
Saphire, E. O., Parren, P. W. H. I., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 942
Self-citationThe 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Convergent Solutions to Binding at a Protein-Protein Interface
DeLano, W. L., Ultsch, M. H., de, A. M., Vos, & Wells, J. A. (2000) · Science · doi:10.1126/science.287.5456.1279 · Cited by 672
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Cited by
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“Importantly, these technologies allow the human antibody constant region isotype — which determines the effector functions activated by immune complexes — to be selected based on its perceived suitability for a given disease indication in vivo”
BackgroundDendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
The function of immunoglobulin A in immunity
Woof, J. M., & Kerr, M. A. (2006) · The Journal of Pathology · doi:10.1002/path.1877 · Cited by 716
Self-citationAnti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 478
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Human plasma protein N-glycosylation
Clerc, F., Reiding, K. R., Jansen, B. C., Kammeijer, G. S. M., Bondt, A., & Wuhrer, M. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-015-9626-2 · Cited by 450
Precision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425
Structure and function relationships in IgA
Woof, J. M., & Russell, M. W. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.39 · Cited by 367
Self-citationRecent Advances in Optical Biosensors for Environmental Monitoring and Early Warning
Long, F., Zhu, A., & Shi, H. (2013) · Sensors · doi:10.3390/s131013928 · Cited by 345
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Lefaucheur, C., Viglietti, D., Bentlejewski, C., Duong van Huyen, J.-P., Vernerey, D., Aubert, O., Verine, J., Jouven, X., Legendre, C., Glotz, D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111120 · Cited by 292
The cytoskeleton in phagocytosis and macropinocytosis
Mylvaganam, S., Freeman, S. A., & Grinstein, S. (2021) · Current Biology · doi:10.1016/j.cub.2021.01.036 · Cited by 263
Woof, J. M., & Mestecky, J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00290.x · Cited by 279
Self-citationIgA: Structure, Function, and Developability
de Sousa-Pereira, P., & Woof, J. M. (2019) · Antibodies · doi:10.3390/antib8040057 · Cited by 264
Self-citationIgA subclasses have different effector functions associated with distinct glycosylation profiles
Steffen, U., Koeleman, C. A., Sokolova, M. V., Bang, H., Kleyer, A., Rech, J., Unterweger, H., Schicht, M., Garreis, F., Hahn, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13992-8 · Cited by 263
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Weissmüller, S., Semmler, L. Y., Kalinke, U., Christians, S., Müller-Berghaus, J., & Waibler, Z. (2012) · Blood · doi:10.1182/blood-2011-12-401083 · Cited by 26
Blundell, P. A., Le, N. P. L., Allen, J., Watanabe, Y., & Pleass, R. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.795047 · Cited by 26
Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation
Gong, Q., Hazen, M., Marshall, B., Crowell, S. R., Ou, Q., Wong, A. W., Phung, W., Vernes, J.-M., Meng, Y. G., Tejada, M., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1189049 · Cited by 26
“These activities include long serum halflife due to binding of the Fc portion to the recycling FcRn receptor,(1) activation of complement-dependent cytotoxicity (CDC) initiated through c1q binding to the Fc,(2) and antibodydependent cell-mediated cytotoxicity (ADCC), which occurs through engagement of Fcg receptors on…”
BackgroundConstruction and periplasmic expression of the Anti-EGFRvIII ScFv antibody gene in Escherichia coli
DEWI, K. S. (2016) · Scientia Pharmaceutica · doi:10.3797/scipharm.isp.2015.06 · Cited by 18
Blundell, P. A., Lu, D., Wilkinson, M., Dell, A., Haslam, S., & Pleass, R. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801337 · Cited by 11
Metadata
- Authors
- Woof, J. M., & Burton, D. R.
- Venue
- Nature Reviews Immunology
- Published
- 2004-02
- Volume
- 4
- Issue
- 2
- Pages
- 89-99
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2087638630
- Cited by
- 387
- References
- 81
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.